Analyst Debanjana Chatterjee of JonesTrading reiterated a Buy rating on Opus Genetics, retaining the price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Debanjana Chatterjee’s rating is based on a combination of factors that highlight Opus Genetics’ promising prospects. The company’s OPGx-LCA5 therapy has shown clinically significant and durable benefits in visual acuity and photoreceptor functionality, which are crucial for patients with little to no baseline vision. Despite some mixed signals in certain test conditions, the overall efficacy and safety profile of the therapy is encouraging, with standardized endpoints providing a clear path forward.
Additionally, concerns about potential cataract formation related to surgery are considered manageable, with strategies in place to mitigate such risks. The company’s strategic focus on advancing into a confirmatory trial is bolstered by the FDA’s guidance on safety and biological plausibility, which OPGx-LCA5 has demonstrated. Furthermore, the anticipated data from the BEST-1 program, which targets a larger patient population, is expected to be a significant catalyst for the company’s stock, reinforcing the Buy rating.
In another report released on September 17, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.